Domain Foundation Models & Evaluation · B2B SaaS Provider
Isomorphic Labs
Alphabet subsidiary developing AI-designed medicines for pharmaceutical partners.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- Isomorphic Labs Limited
- Entity type
- COMPANY
- Founded
- 2021
- Headquarters
- United Kingdom
- Company size
- 201–500
- Market cluster / sector
- Domain Foundation Models & Evaluation
- Market role
- B2B SaaS Provider
- Official website
- isomorphiclabs.com
What Isomorphic Labs does
Isomorphic Labs operates a proprietary AI-enabled drug-discovery and development model. It applies IsoDDE to internal therapeutic programmes and pharmaceutical collaborations, combining computational design capabilities with partners’ disease biology, drug-development infrastructure and downstream clinical resources. Value is created by prioritising, generating and refining candidate medicines before laboratory testing, reducing experimental iteration and expanding the addressable target and modality set.
Category differentiation
Isomorphic Labs is a drug-design and therapeutic-development subsidiary, not a general-purpose foundation-model provider or a public drug database. Its platform is deployed through internal research and pharmaceutical collaborations rather than public self-service software.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Isomorphic Labs Limited is Alphabet Inc.'s UK-based AI drug-design subsidiary, founded from Alphabet’s DeepMind in 2021. It develops and deploys the proprietary Isomorphic Labs Drug Design Engine (IsoDDE), which combines predictive and generative models for molecular design, biomolecular structure and interaction prediction, binding-affinity prediction, binding-pocket identification and computational refinement of drug candidates. The platform supports small molecules, antibodies, peptides and molecular glues across therapeutic areas. The company serves pharmaceutical and biotechnology organisations through strategic research collaborations, while applying the same platform to internally owned drug-development programmes. It generates commercial value through bespoke partner research programmes and associated collaboration economics, rather than public self-serve SaaS subscriptions. Alphabet remains the ultimate controlling party; external investors have financed scale-up of the AI engine and candidate pipeline.
Company news briefing
Briefing updated:
Isomorphic Labs is reportedly in early-stage talks to raise approximately $5 billion at a $50 billion valuation following previous funding rounds totalling nearly $7.7 billion within 18 months. Led by Demis Hassabis, the Alphabet spin-off continues to advance its AI-driven drug discovery platform while preparing to test its first drug candidate by the end of 2026. Revenue is currently anchored by prominent pharmaceutical partnerships with Eli Lilly, Novartis, and Johnson & Johnson.
Business model & monetisation
Isomorphic Labs monetises through bespoke strategic research collaborations with pharmaceutical companies and value created in internal drug-development programmes. Collaboration economics can include research funding, milestone payments and downstream value participation; public materials do not disclose standard software licences, usage pricing, subscription tiers or public SaaS access. Its 2024 statutory accounts recorded nil turnover, so reported commercial revenue remains early-stage relative to its platform-development investment.
- Pharmaceutical research collaborations
- Bespoke service and collaboration agreements
- Milestone and downstream collaboration economics
- Performance-linked payments and value participation
- Internal drug-development programmes
- Therapeutic asset creation
Products & capabilities
No products with linked sources are available in this view.
Unlock Full Intelligence Profile for Isomorphic Labs
Get unlimited access to corporate ownership, historical M&A transactions, verified tech stack telemetry, and live market signals in the interactive Knowledge Graph.
Verified Ownership & Corporate Hierarchy
Complete corporate hierarchy traversal, shareholder cap table history, and parent holding links sourced from regulatory filings.
360° Tech Stack & Vendor Telemetry
Technical header bidding configurations, sellers.json registry nodes, CMP disclosures, and direct programmatic supply chains.
Live Market Signals & Executive Briefings
Continuous 24/7 monitoring of material M&A deals, executive shifts, product rollouts, and hiring trends across peer entities.
Competitors & alternatives
Track competitor shifts
Receive automated telemetry on strategic moves, acquisitions, and market share shifts across Isomorphic Labs's competitive landscape.
AI product discovery SaaS for faster product-market fit.
Builds multimodal foundation models and fine-tuning infrastructure.
Efficient foundation models and deployment tools for private edge AI.
Enterprise predictive analytics and decision automation SaaS.
Sovereign European AI platform for regulated enterprise and public-sector workflows.
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
Isomorphic Labs seeks $5B round at $50B valuation
Financials · Recorded impact score: 4/5
Isomorphic Labs, Alphabet's AI drug discovery spinout led by Demis Hassabis, is reportedly in early-stage talks to raise approximately $5 billion at a valuation of around $50 billion, according to Bloomberg. This round would follow a $2.1 billion Series B in May and a $600 million round in 2025, bringing total raised to nearly $7.7 billion within 18 months. Despite the massive funding, the company has not yet tested any drug candidate in humans; clinical trials were initially planned for end of 2025, then delayed to late 2026. Investors are valuing the platform rather than a product, a record for a pre-clinical biotech. Revenue currently comes from partnerships with Eli Lilly, Novartis, and Johnson & Johnson, with milestone-based payments potentially reaching up to $2.9 billion. Skepticism remains, as Eli Lilly's CEO Dave Ricks has questioned the effectiveness of AI in drug discovery, noting that protein structure prediction is just one part of the challenge.
- Isomorphic Labs is in early talks to raise about $5 billion at a valuation of about $50 billion.
- The company has not yet tested any drug candidate in humans; clinical trials were postponed to end of 2026.
Hassabis: AGI in two to three years
AI · Recorded impact score: 4/5
Demis Hassabis, CEO of Google DeepMind, now predicts artificial general intelligence (AGI) will be achieved within two to three years, revising his earlier estimate of three to five years. Speaking to The Wall Street Journal, he cited rapid progress in AI capabilities. However, at the International AI Summit in Dublin, he warned of a severe AI safety incident within the next two years unless standards are raised, pointing to recent breaches by AI agents, including those that bypassed Alibaba's bot protection. His timeline aligns with industry optimism, but Meta's former chief scientist Yann LeCun disagrees, arguing that large language models won't lead to human-level intelligence and advocating for world models instead. LeCun's startup AMI Labs raised about $1 billion for this approach. Additionally, Hassabis's drug discovery spin-off Isomorphic Labs aims to test its first drug by the end of 2026.
- Demis Hassabis predicts AGI in 2-3 years, revising his earlier estimate of 3-5 years.
- Hassabis warned of a severe AI safety incident within two years at the International AI Summit in Dublin.
Careers & open positions
Open positions indexed from verified career portals and applicant tracking systems.
| Position | Department | Location | Posted |
|---|---|---|---|
| Research Leader / Senior Research Investigator (Translational Biology & In-Vitro Pharmacology), London(Lead) | DDMR | London | |
| Medicinal Drug Design Lead, London(Lead) | DDMR | London | |
| Research Leader (In-vitro Pharmacology, Exploratory Sciences), London(Lead) | DDMR | London | |
| Principal, Corporate Development, London(Director) | Central | London | |
| Research Investigator / Senior Research Investigator (In-vitro Pharmacology, Exploratory Sciences), London(Mid-Level) | DDMR | London |
Explore company relationships
Questions about Isomorphic Labs
What is Isomorphic Labs?
Isomorphic Labs is an Alphabet subsidiary that uses proprietary predictive and generative AI models to design and develop potential medicines.
Who uses Isomorphic Labs?
Pharmaceutical and biotechnology companies, including Novartis, Eli Lilly and Johnson & Johnson, use its capabilities through strategic research collaborations.
How does Isomorphic Labs make money?
It monetises bespoke pharmaceutical research collaborations and associated milestone-based economics, while building value in internal drug-development programmes.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
2 publicly documented primary sources and citations linked across the market graph.
Continue your research on Isomorphic Labs
Open additional company details, personal Watchlists and your Strategic Intelligence Agent in Polaris7. It monitors your market daily and delivers tailored briefings with clear strategic context whenever relevant news occurs.
Daily intelligent monitoring · Verified primary sources.
Unlock full intelligence profile, ownership & live market signals
